Small interfering RNAs in the management of human rheumatoid arthritis

1Rheumatoid arthritis (RA) is a chronic autoimmune disease that primarily affects the small joints.

2Joints are often hot, swollen and painful. The most commonly affected sites are the wrists and hands on both sides. Other less-affected sites are skin, heart, eyes, lung, blood and nerves. Inflammation of the lungs and heart and reduced number of red blood cells can occur. Systemic symptoms may include fever, asthenia and consequent weight loss. Symptoms often evolve slowly and manifest within weeks or months. The cause of RA is not entirely clear, and it is hypothesized that it is a multifactorial mechanism that includes both genetic and environmental factors. The pathological mechanism is determined by an autoimmune reaction, where the immune system attacks the joints. There is inflammation and thickening of the joint capsule with involvement of the bones and underlying cartilage. Although the diagnosis is clinical, laboratory tests and radiographs are used to confirm it and rule out other conditions. To diagnose RA, it is necessary to exclude other pathologies that can present in a similar way, including psoriatic arthritis, systemic lupus erythematosus and fibromyalgia.

3In recent years, more attention has been paid to the natural processes of regulation of eukaryotic genes, in particular RNA interference (RNAi)., The aim is to use this mechanism in genomic research and in the formulation of suitable therapies. Usually, a small interfering RNA (siRNA) is composed of about 20 nucleotides arranged to form a double-stranded RNA molecule.

4The RNAi mechanism involves various elements such as detection wire (passenger wire), sense wire (guide wire), enzymes such as dicer, argonaute and the central part RNA-induced silencing complex (RISC). The guide wire is a nucleotide sequence recognized by Dicer, which selects it and integrates it into RISC. The guide wire is used to recognize the passenger wire, which will be degraded by RISC.

5With the study of the physiological role of siRNAs and the understanding of their mechanism of action, it is easier to find a therapeutic application that is targeted on the expression of specific genes. The field of application is varied, and includes endocrinological abnormalities, hepatitis, tumors and pathologies triggered by external agents such as viruses.

6Small interfering RNAs selectively target a gene and silence it, inhibiting the expression of the gene that determines the pathology under study.

7To date, the sequence of 4894 chemically modified siRNAs is available.

8The mechanism of action of siRNA is very effective for the study of human genomics and for the development of possible therapies, but it has an intrinsic issue, as siRNAs are easily degradable by nucleases, which give them a short half-life. To improve their stability and determine a better half-life and efficacy, chemical modifications have been made. 128 unique chemical changes were analyzed at different locations with various permutations, specific combinations or additions such as the modification of fluorine to 2-OH at different nucleotide positions of siRNA to maintain silencing power and increase thermal stability.

9In RA, the autoimmune response and inflammatory response are mediated by numerous cytokines that result in a self-sustaining cascade reaction.

10Some authors have tried to use siRNAs to block some biological signaling pathways, thereby blocking the inflammatory response., Other authors have instead used siRNAs to evaluate and monitor the inflammatory and autoimmune response after the administration of specific drugs.

11This review evaluates the current scientific evidence on the use of siRNAs in RA therapy.

12Only published articles performed with human cells were selected.

13The review follows the Preferred reporting items for systematic reviews and meta-analyses (PRISMA) (Fig. 1).

14All published investigations reported the possible role of siRNA in RA therapy according to a priori established inclusion criteria.

15Studies in language other than English were included from the present investigation. Narrative and systematic reviews, meta-analyses, technical notes and case reports were excluded.

16Articles in all languages were included, with no time limit for publication. All techniques of using siRNAs in RA therapy were included.

17Two investigators independently conducted the systematic search, through March 2022, from the full-text archives of Embase, Google Scholar, Scopus and PubMed. In the search, we used combinations of the following key terms: RA, siRNA, short interfering RNA, silencing RNA, RNAi, with no limit of the year of publication. Two investigators independently examined the titles and abstracts to remove duplicates, and evaluated the eligible studies according to the preestablished inclusion criteria. If titles and abstracts did not allow to decide on inclusion or exclusion, the relevant full text was examined. The bibliographies of the articles included were reviewed by hand to identify further related articles. If discrepancies persisted, discussion with the senior investigator allowed to resolve them.

18Twenty studies satisfied the inclusion criteria, and were thus included in the analysis. The details of the search are detailed in the flowchart in Figure 1.

19A total of 994 articles were identified by the search engines used and the duplicates were subsequently removed, obtaining 583 articles. At this point, 391 articles were excluded after reading the titles and abstracts. Narrative and systematic reviews, meta-analyses, technical notes and case reports were excluded. There were 104 articles left and 84 articles were excluded as they were not appropriate for the topics covered or for the incomplete amount of information possessed.

20Twenty studies met the inclusion criteria, data were extracted and collected in Table 1.

21Of these studies, 15 used siRNAs to silence specific genes and then identify gene and protein targets to produce targeted therapy. Another five studies used siRNAs to monitor the function of some RA drugs.

22No scientific studies were identified on human cells and siRNA on the topic of RA before 2012.

23Lee et al. evaluated hypoxia in the pathogenesis of RA. They cultured two groups of fibroblasts, the first under hypoxic conditions and the second in normoxic conditions under stimulation with interleukin 1 beta (IL-1β). The inflammatory response was assessed by measuring the values of vascular endothelial growth factor (VEGF), metalloproteinase (MMP)-1 and MMP-13 in the two cell groups. The group of fibroblasts in hypoxic conditions was transfected with siRNA specific for hypoxia-inducible factor-1α (HIF-1α). The differential expression of MMP under the combined effect of IL-1β and hypoxia was significantly attenuated by silencing HIF-1α with siRNA.

24Small interfering RNAs have been used to determine the effect of some proteins in regulating the inflammatory processes in RA, to identify these proteins and their possible use as a therapeutic target. In this regard, Chen et al., studying the enzyme arginine methyltransferase 5 (PRMT5) found that this enzyme increases in fibroblast-like synoviocytes (FLS) from patients with RA. In siRNA-treated cells, they demonstrated reduced production of IL-6 and IL-8 and proliferation of RA FLS.

25Xu et al. analyzed cysteine-rich protein 61 (Cyr61), a product of an immediately early gene. Cyr61 is directly correlated with adhesion, cell migration and stimulation of production of specific inflammatory cytokines. Experimentally, Cyr61-siRNA reduced matrix MMP-3 and MMP-13 levels and induced apoptosis in RA FLS cells. In addition, a specific monoclonal antibody against Cyr61 showed good results in reducing inflammation in RA in mice. Based on the results obtained, the authors began testing a similar monoclonal antibody on humans.

26To silence a specific gene, siRNAs must be delivered effectively. Nogueira et al. evaluated the efficiency of folate-targeted liposomes for specific delivery of siRNA to activated macrophages, key effector cells in RA pathology that specifically express the folate receptorβ. They incorporated human liposomes with siRNA-myeloid cell leukemia-1 (Mcl-1).

27Myeloid cell leukemia-1 is a protein essential for the survival of synovial macrophages.

28The liposomal formulation used by Nogueira et al. was effective in the transport of siRNA-Mcl-1, inhibiting Mcl-1 expression in treated human macrophages.

29An additional gene target for RA therapy has been proposed by Wang et al. They developed a peptide–polycation lipid-protamine-DNA (LPD) conjugated cell-permeable complex loaded with ribonucleotide reductase M2 (RRM2) siRNA (CCP-LPDR), aiming to increase apoptosis levels and inhibit proliferation of RA FLS. CCP-LPDR is a small molecule (~130 nm) with a high siRNA encapsulation efficiency ( >90%) and high stability. This resulted in approximately 80% suppression of RRM2 gene and protein expression. In particular, CCP-LPDR resulted in a marked decrease in proliferation and an increase in the level of apoptosis in RA FLS. In addition, the levels of proinflammatory cytokines, tumor necrosis factor alfa (TNF-α) and IL-6, were decreased in RA FLS after treatment with CCP-LPDR.

30A much better-known mediator was studied by Peng et al., who inhibited cyclooxygenase-2 (COX-2) by a specific siRNA, responsible for the inflammatory response and particularly active in RA.

31COX-2 is involved in the inflammatory response via some mediators, including triggering receptor expressed on myeloid cells-1 (TREM-1).

32TREM-1 is directly connected and overexpressed by the cytokines produced through COX-2, and determines the activation of the inflammatory response by acting on monocytes/macrophages, lymphocytes and mast cells. TREM-1 may be a good therapeutic target in human RA.

33Silencing of melanoma differentiation-associated gene 5 and nuclear factor erythroid 2 by specific siRNAs demonstrated a reduction in the inflammatory process in FLS in vitro.,

34Wang et al. instead studied the effect of VEGF in maintaining the inflammatory process in RA.

35Other authors have used siRNA in cell cycle regulation, migration and cell apoptosis in both B and inflammatory RA cells.

36The biological mechanism of siRNAs has been used to identify the target proteins and genes,,, of some already existing drugs,,,,, to test their efficacy in RA.

37Ikuta et al. analyzed the specificity protein 1 (Sp1) protein that binds the promoter of the gliostatin gene (GLS). Gliostatin/thymidine phosphorylase has angiogenic and arthritogenic activities, and aberrant GLS production has been observed in the active synovial membranes of RA patients. The use of the drug mithramycin reduced the expression of Sp1 and GLS in RA FLS, thus defining mithramycin as a useful RA drug.

38Some authors have experimentally used a therapeutic combination (siRNA-COX-2 and dexamethasone). The two drugs were inserted into poly (DL-lactic-co-glycolic acid) nanoparticles that directed them into target cells (immortalized chondrocyte cell line C-28/I2). The result was apoptosis of 30% of the cells analyzed and the reduction of COX-2 expression. The combined therapy was shown useful in the treatment of RA.

39Li et al. conducted a twofold study. They analyzed the effects of siRNA-high-mobility group box 1 (HMGB1) on FLS and studied the therapeutic effects of methotrexate (MTX) in RA. HMGB1 is actually overexpressed in RA patients, and its activity is reduced by using siRNA-HMGB1. This effect is evident in the reduction of matrix MMP-2 and MMP-13 present in the RA. Methotrexate in turn resulted in a reduction in HMGB1, thus showing itself to be a good anti-RA drug.

40Municio et al. also studied the therapeutic effects of MTX. Their study was conducted on granulocyte-macrophage colony-stimulating factor (GM-CSF) or macrophage CSF polarized macrophages. To analyze the molecular pathways stimulated in the RA process, and therefore the function of MTX, they used specific siRNA. Thymidylate synthase (TS) and protein 53 (p53) were expressed by polarized cluster of differentiation (CD)163 +/TNF-α + GM-CSF macrophages from RA joints but not normal synovium. The macrophage response to MTX is polarization-dependent and determined by the TS-p53 axis.

41Li et al. investigated the immunological mechanisms by which arsenic trioxide (As2O3) can inhibit the differentiation of T helper 17 (Th17) cells by promoting the generation of regulatory T (Treg) cells by modulating the signal transducer and activator of transcription 3 (STAT3) in treatment-naïve RA patients. To test the mechanism of As2O3 on Th17–Treg balance in vitro, they conducted STAT3 transfection experiments with siRNAs. Arsenic trioxide may be a potential immunomodulator for treatment-naïve RA patients that helps balance Treg and Th17 cells through modulation of STAT3.

42Ma et al. compared the action of the antimalarial drug artesunate by comparing it to two other drugs, hydroxychloroquine and MTX, using FLS from RA patients. Biological pathways were investigated and tested by phosphoinositide-dependent kinase-1 (PDK-1) knockdown by siRNA transfection. Artesunate inhibited RA FLS migration and invasion through the suppression of PDK1-induced activation of protein kinase B and ribosomal S6 kinase 2phosphorylation. Artesunate exerted greater anti-inflammatory effects than hydroxychloroquine and similar to MTX. In vitro, MTX and artesunate also had a synergistic effect on the inhibition of RA processes. Artesunate may be a potential disease-modifying antirheumatic drug for RA.

43RA is the most severe condition in terms of structural damage to the joints, secondary bone damage, extra-articular complications, associated comorbidities and risk of mortality. In RA, as with other autoimmune diseases, the immune system attacks healthy tissues, not recognizing them as such. The preferred target of antibodies in RA is the synovial membrane. The membrane reacts to such proinflammatory stimuli by increasing in volume and giving rise to abundant synovial tissue. This expands to cause gradual destruction of articular cartilage, but the proliferative process in severe cases reaches the bones and other surrounding tissues, including subchondral bone, capsules, tendons and ligaments. RA produces marked disability.

44The cause of RA is not yet fully known, but its pathogenesis is multifactorial.

45Our current study focuses on possible therapies and the possibility of using siRNAs as therapy or in the experimentation of new drugs.

46Authors have carried out studies on human cells, FLS, chondrocyte, monocytes/macrophages, lymphocytes and mast cells. The aim was to highlight the organic pathways and the molecular targets on which it is possible to intervene.

47All cell types, and mainly fibroblasts, overexpress IL-1, TNF-α and TNF-β in patients with AR.

48TNF-α, a cytokine involved in systemic inflammation, is a member of a group of cytokines that stimulates the reaction of the acute phase. It is produced by T-CD4+ lymphocytes, natural killer (NK) cells, neutrophiles, mast cells, eosinophilic and neurons. TNF-α is the main cell regulator of the immune system.

49Proinflammatory cytokines can influence VEGF and MMP gene expression in synoviocytes during progressive inflammation. In RA, joint inflammation and the production of proinflammatory cytokines, including IL-1 and TNF-α, stimulate synovial fibroblasts to produce large amounts of MMP.,

50The expression of MMP is significantly reduced when TNF-α blocking agents are used.,

51There are about 20 different members of the MMP family., Of these, MMP-1 and MMP-13 seem to be the most important in the degradation of cartilage in RA because they limit the rate of collagen degradation., MMP-1 and MMP-13 are the only ones able to split the native triple helix of collagen, allowing it to unwind from the chains; after unwinding, the chains may undergo further degradation by other MMPs.

52In animal models, inhibitors with varying degrees of selectivity for different MMPs showed cartilage protective activity in AR. However, the development of MMP inhibitors as therapeutic agents in clinical trials has been hindered by side effects., Therefore, the factors influencing individual MMP expression require further clarification to allow efficient control of MMP expression in clinical treatments.

53IL-1β and TNF-α are proinflammatory cytokines that play an important role in RA. They denature the associated cartilage matrix through the production of MMP, and induce the consequent reduction in the production of proteoglycans and collagen., IL-1β and TNF-α promote the expression of the inflammation-related genes COX-2 and inducible nitric oxide synthase,, resulting in high levels of prostaglandin E2 and nitric oxide production, respectively.,

54COX-2 is both inducible and constitutive (in the central nervous system, kidneys and intestines).

55Specific stimulatory events activate and regulate COX-2, which, in turn, activates the biosynthesis of prostanoids involved in inflammation.

56COX-2 expression is upregulated in autoimmune diseases such as RA and in many neoplasms.

57In vivo studies have shown the effectiveness of using siRNA in pathologies other than AR.,

58Jyotsana et al. have shown that RNAi therapies can be used against leukemia cells and promise new treatment options for leukemia patients.

59The reguardies who study autoimmune diseases aim to find a highly selective therapy that only acts on the pathological inflammatory process. Numerous drugs have been proposed in RA but none is entirely specific. The purpose of using siRNAs is 2-fold. On the one hand, they can be used to accurately determine the genes and molecules involved in RA; on the other, they can be used as a target therapy.

60Numerous drugs have been tested in animal cells. We analyzed the results obtained with siRNAs in human cell therapy. In vitro, the results are satisfactory, demonstrating their possible application in vivo. Gene therapy is the future for many pathologies, and its application may be useful in RA, a condition in which we do not know the causes but we know the molecular targets on which we can act.

61Any data are reported.